General Information of Drug (ID: DMMHR1U)

Drug Name
Denileukin diftitox Drug Info
Indication
Disease Entry ICD 11 Status REF
Epithelial ovarian cancer 2B5D Approved [1]
leukaemia 2A60-2B33 Approved [2]
Plasma cell myeloma 2A83.1 Approved [1]
Primary cutaneous T-cell lymphoma Approved [3]
Non-small-cell lung cancer 2C25.Y Phase 2 [2]
Therapeutic Class
Anticancer Agents
Cross-matching ID
TTD Drug ID
DMMHR1U

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ALKS 4230 DME3ZYC Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
Ro26-4550 DMGL7TM Discovery agent N.A. Investigative [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 2 receptor (IL2R) TTAJU0S NOUNIPROTAC Binder [4]

References

1 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7044).
3 Advanced-stage primary cutaneous T-cell lymphoma treated with bexarotene and denileukin diftitox. Case Rep Dermatol. 2011 Jan;3(1):13-7.
4 Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69.
5 ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2297).